These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 26739998)

  • 1. Phase II study of oxaliplatin combined with S-1 and leucovorin (SOL) for Chinese patients with metastatic colorectal cancer.
    Wang ZQ; Zhang DS; Xu N; Luo DY; Deng YH; Wang FH; Luo HY; Qiu MZ; Li YH; Xu RH
    Chin J Cancer; 2016 Jan; 35():8. PubMed ID: 26739998
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Multicenter Feasibility Study with S-1, Oxaliplatin and Oral Leucovorin (SOL) for the Patients with Untreated Metastatic Colorectal Cancer: The Result of Final Analysis.
    Lu M; Wang Y; Liu W; Bai C; Xu J; Shen L
    Hepatogastroenterology; 2014 Jun; 61(132):1018-23. PubMed ID: 26158159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized phase II study of combination therapy with S-1, oral leucovorin, and oxaliplatin (SOL) and mFOLFOX6 in patients with previously untreated metastatic colorectal cancer.
    Yamazaki K; Kuwano H; Ojima H; Otsuji T; Kato T; Shimada K; Hyodo I; Nishina T; Shirao K; Esaki T; Ohishi T; Denda T; Takeuchi M; Boku N
    Cancer Chemother Pharmacol; 2015 Mar; 75(3):569-77. PubMed ID: 25575764
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial.
    Yamada Y; Takahari D; Matsumoto H; Baba H; Nakamura M; Yoshida K; Yoshida M; Iwamoto S; Shimada K; Komatsu Y; Sasaki Y; Satoh T; Takahashi K; Mishima H; Muro K; Watanabe M; Sakata Y; Morita S; Shimada Y; Sugihara K
    Lancet Oncol; 2013 Dec; 14(13):1278-86. PubMed ID: 24225157
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase II study of S-1, oxaliplatin, oral leucovorin, and bevacizumab combination therapy (SOLA) in patients with unresectable metastatic colorectal cancer.
    Nishina T; Kato T; Yamazaki K; Yoshino T; Miyata Y; Esaki T; Moriwaki T; Boku N; Hyodo I
    Cancer Chemother Pharmacol; 2015 Sep; 76(3):547-53. PubMed ID: 26198316
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I clinical and pharmacokinetic/pharmacogenetic study of a triplet regimen of S-1/irinotecan/oxaliplatin in patients with metastatic colorectal or gastric cancer.
    Park SR; Hong YS; Lim HS; Seong MW; Kong SY; Kim SY; Park YI; Jung KH
    Cancer Chemother Pharmacol; 2013 Nov; 72(5):953-64. PubMed ID: 23982118
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A single-arm phase II trial of combined chemotherapy with S-1, oral leucovorin, and bevacizumab in heavily pre-treated patients with metastatic colorectal cancer.
    Yamaguchi K; Taniguchi H; Komori A; Narita Y; Nitta S; Nomura M; Kadowaki S; Takahari D; Ura T; Andoh M; Muro K; Mori K; Igarashi Y
    BMC Cancer; 2015 Aug; 15():601. PubMed ID: 26311588
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II study of S-1 plus leucovorin in patients with metastatic colorectal cancer: Regimen of 1 week on, 1 week off.
    Li J; Xu R; Xu J; Denda T; Ikejiri K; Shen L; Toh Y; Shimada K; Kato T; Sakai K; Yamamoto M; Mishima H; Wang J; Baba H
    Cancer Sci; 2017 Oct; 108(10):2045-2051. PubMed ID: 28763145
    [TBL] [Abstract][Full Text] [Related]  

  • 9. S-1 and irinotecan with or without bevacizumab versus 5-fluorouracil and leucovorin plus oxaliplatin with or without bevacizumab in metastatic colorectal cancer: a pooled analysis of four phase II studies.
    Iwasa S; Nagashima K; Yamaguchi T; Matsumoto H; Ichikawa Y; Goto A; Yasui H; Kato K; Okita NT; Shimada Y; Yamada Y
    Cancer Chemother Pharmacol; 2015 Sep; 76(3):605-14. PubMed ID: 26220845
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II study of S-1 plus leucovorin in patients with metastatic colorectal cancer.
    Koizumi W; Boku N; Yamaguchi K; Miyata Y; Sawaki A; Kato T; Toh Y; Hyodo I; Nishina T; Furuhata T; Miyashita K; Okada Y
    Ann Oncol; 2010 Apr; 21(4):766-771. PubMed ID: 19828562
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II study of irinotecan/S-1 combination chemotherapy for patients with oxaliplatin-refractory colorectal cancer.
    Oh SY; Ju YT; Choi SK; Ha CY; Lee WS; Kim HG; Lee GW; Kwon HC; Kang JH
    Invest New Drugs; 2011 Oct; 29(5):1050-6. PubMed ID: 20238142
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study).
    Muro K; Boku N; Shimada Y; Tsuji A; Sameshima S; Baba H; Satoh T; Denda T; Ina K; Nishina T; Yamaguchi K; Takiuchi H; Esaki T; Tokunaga S; Kuwano H; Komatsu Y; Watanabe M; Hyodo I; Morita S; Sugihara K
    Lancet Oncol; 2010 Sep; 11(9):853-60. PubMed ID: 20708966
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase II study of S-1 plus irinotecan and oxaliplatin in heavily-treated patients with metastatic colorectal cancer.
    Kim SY; Hong YS; Kim BC; Park JW; Choi HS; Jeong SY; Kim DY; Hong CW; Sohn DK; Jung KH
    Invest New Drugs; 2009 Jun; 27(3):269-74. PubMed ID: 18815728
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biweekly oxaliplatin plus irinotecan and folinic acid-modulated 5-fluorouracil: a phase II study in pretreated patients with metastatic colorectal cancer.
    Comella P; Massidda B; Palmeri S; Putzu C; De Rosa V; Izzo F; Fiore F; Casaretti R; Sandomenico C
    Anticancer Drugs; 2006 Sep; 17(8):985-92. PubMed ID: 16940809
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II study of docetaxel, oxaliplatin, and S-1 therapy in patients with metastatic gastric cancer.
    Kim HS; Ryu MH; Zang DY; Ryoo BY; Yang DH; Cho JW; Lim MS; Kim MJ; Han B; Choi DR; Kim JH; Jung JY; Song H; Park CK; Kang YK
    Gastric Cancer; 2016 Apr; 19(2):579-585. PubMed ID: 25997815
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Experience with S-1 in older Caucasian patients with metastatic colorectal cancer (mCRC): Findings from an observational chart review.
    Winther SB; Zubcevic K; Qvortrup C; Vestermark LW; Jensen HA; Krogh M; Sorbye H; Pfeiffer P;
    Acta Oncol; 2016 Jul; 55(7):881-5. PubMed ID: 27181284
    [TBL] [Abstract][Full Text] [Related]  

  • 17. S-1 and irinotecan plus bevacizumab as second-line chemotherapy for patients with oxaliplatin-refractory metastatic colorectal cancer: a multicenter phase II study in Japan (KSCC1102).
    Miyamoto Y; Tsuji A; Tanioka H; Maekawa S; Kawanaka H; Kitazono M; Oki E; Emi Y; Murakami H; Ogata Y; Saeki H; Shimokawa M; Natsugoe S; Akagi Y; Baba H; Maehara Y
    Int J Clin Oncol; 2016 Aug; 21(4):705-712. PubMed ID: 26746689
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II study with oxaliplatin and S-1 for patients with metastatic colorectal cancer.
    Zang DY; Lee BH; Park HC; Song HH; Kim HJ; Jung JY; Kim JH; Kim HY; Kwon JH; Hwang SW; Park SR; Park CH; Kim KO; Kim MJ; Jang KM
    Ann Oncol; 2009 May; 20(5):892-6. PubMed ID: 19153122
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modified FOLFOX6 with oxaliplatin stop-and-go strategy and oral S-1 maintenance therapy in advanced colorectal cancer: CCOG-0704 study.
    Nakayama G; Kodera Y; Yokoyama H; Okuda N; Watanabe T; Tanaka C; Iwata N; Ohashi N; Koike M; Fujiwara M; Nakao A
    Int J Clin Oncol; 2011 Oct; 16(5):506-11. PubMed ID: 21431344
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II trial of oxaliplatin and tegafur/uracil and oral folinic acid for advanced or metastatic colorectal cancer in elderly patients.
    Rosati G; Cordio S; Tucci A; Blanco G; Bordonaro R; Reggiardo G; Manzione L
    Oncology; 2005; 69(2):122-9. PubMed ID: 16118508
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.